Disease · MONDO_0004988

breast adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. breast adenocarcinoma. Diseases, record MONDO_0004988. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004988

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: breast adenocarcinoma; Open Targets
Open Targets ID: MONDO_0004988; Open Targets
Other names: adenocarcinoma of breast, adenocarcinoma of the breast, mammary adenocarcinoma; Open Targets
Disease Ontology: DOID:3458; Disease Ontology
NCI Thesaurus: C5214; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 7 of its 29 drugs, from ClinicalTrials.gov; Open Targets

Drugs29

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
TAMOXIFEN	CHEMBL83	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TAMOXIFEN CITRATE	CHEMBL786	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
LAPATINIB	CHEMBL554	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 29

See all 29 drugs

Targets39

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	4	Epidermal growth factor receptor erbB1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/1956	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	3	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 2/3	https://conductscience.org/library/genes/2064	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 39

See all 39 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02301988	A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer	Phase 2	151	2018-09-20	Breast Cancer	IPATASERTIB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01097642	Neo-Adjuvant Study in Triple Negative Breast Cancer Patients	Phase 2	40	2021-08-10	Breast Cancer	CETUXIMAB, IXABEPILONE	Its record names the disease	ClinicalTrials.gov
NCT00086957	Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer	Phase 1/2	31	2017-02-27	Breast Cancer	DOCETAXEL, GEFITINIB, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00002707	Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed	Phase 3	2,411		Breast Cancer	CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, TAMOXIFEN	Its record names the disease	ClinicalTrials.gov
NCT00929591	SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer	Phase 3	1,558		Breast Cancer	CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL, TAMOXIFEN	Its record names the disease	ClinicalTrials.gov
NCT03085368	A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin	Phase 2/3	482		HER2-positive Breast Cancer	LAPATINIB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00949598	Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer	Phase 3	177		Breast Cancer	LETROZOLE, TAMOXIFEN CITRATE	Its record names the disease	ClinicalTrials.gov
NCT01367028	A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer	Phase 2	100		Breast Cancer	BEVACIZUMAB, DOCETAXEL, DOXORUBICIN, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02448420	Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer	Phase 2	73		Metastatic Breast Cancer	LETROZOLE, PALBOCICLIB, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00002780	Biological Therapy in Treating Women With Metastatic Breast Cancer	Phase 1/2	60		Breast Cancer	ALDESLEUKIN, CARBOPLATIN, CYCLOPHOSPHAMIDE, SARGRAMOSTIM, THIOTEPA	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ipatasertib + Paclitaxel vs Placebo + Paclitaxel: deaths from any cause	1 of 76	0 of 75	151	NCT02301988	Trial comparisons
Ipatasertib + Paclitaxel vs Placebo + Paclitaxel: serious adverse events	10 of 76	3 of 75	151	NCT02301988	Trial comparisons
Ixabepilone vs Ixabepilone Plus Cetuximab: Complete Response Rate	2 of 15	8 of 25	40	NCT01097642	Trial comparisons
Ixabepilone vs Ixabepilone Plus Cetuximab: Recurrence Free Survival (RFS)	9 of 15	17 of 25	40	NCT01097642	Trial comparisons
Ixabepilone vs Ixabepilone Plus Cetuximab: deaths from any cause	0 of 15	0 of 25	40	NCT01097642	Trial comparisons
Ixabepilone vs Ixabepilone Plus Cetuximab: Safety and Toxicity of Both Treatment Regimens: Number of Participants With Adverse Events	15 of 15	25 of 25	40	NCT01097642	Trial comparisons
Ixabepilone vs Ixabepilone Plus Cetuximab: serious adverse events	2 of 15	6 of 25	40	NCT01097642	Trial comparisons
Dose Level 1 - Docetaxel 75 mg/m^2 vs Dose Level 2 - Docetaxel 60 mg/m^2: serious adverse events	2 of 2	7 of 29	31	NCT00086957	Trial comparisons

Papers from its trials29

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26598744	RESULT	1	PubMed
23234763	RESULT	1	PubMed
20185313	RESULT	1	PubMed
17679724	RESULT	1	PubMed
16606972	RESULT	1	PubMed
16539726	RESULT	1	PubMed
15934498	RESULT	1	PubMed
15837984	RESULT	1	PubMed
15383473	RESULT	1	PubMed
14559892	RESULT	1	PubMed

1 to 10 of 29

See all 29 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004988

GET https://conductscience.org/api/diseases/v1/MONDO_0004988/drugs?page=2

API reference For AI assistants